Semax vs Selank Evidence and US Compounding Status Compared

Semax and Selank answer different clinical questions. Semax has been studied mainly for stroke recovery and cognition, while Selank has been studied for anxiety. Neither peptide has enough evidence to be considered proven, and neither is approved by the U.S. Food and Drug Administration (FDA). The current U.S. distinction is regulatory: Semax free base appears in a draft compounding policy from the U.S. Department of Health and Human Services (HHS) for intranasal use, while Selank does not.

The Comparison at a Glance

Semax and Selank share part of their peptide structure, but their human evidence and U.S. regulatory paths differ.

None of these studies shows that either peptide will improve your symptoms. A physician uses them to match each peptide to the question it was studied for and to the U.S. rules that apply.

One symptom or one lab value cannot identify the driver by itself. A physician needs the pattern across your history, symptoms, and related biomarkers before choosing a treatment.

The Question Each Peptide Answers

Semax is the closer match when your question concerns stroke recovery or cognitive function. Selank is the closer match when your question concerns anxiety.

A 2022 review placed Semax in the nootropic group and Selank in the anxiolytic group among peptide drugs developed in Russia.² Their evidence followed those categories.

For Semax, the practical question is whether the Russian stroke and cognition findings are reliable enough to inform care. FDA reviewed Semax for cerebral ischemia, migraine, and trigeminal neuralgia and found insufficient evidence for those uses.¹ Semax has a clinical research history, but the available record does not establish effectiveness.

For Selank, the practical question is whether small active-comparator trials support its use for anxiety. The trials report favorable findings, but their designs make it difficult to separate a Selank effect from expectation, study conduct, or the effect of another medication.^4-6

If anxiety is affecting your daily life, a physician should assess the symptoms and their causes before discussing an experimental peptide. Approved treatments have a larger clinical record. Sleep, substance use, medication effects, thyroid function, and ongoing stress can also shape the plan. Practical steps for reducing stress are covered in our guide to how to destress.

Selank’s Human Anxiety Evidence

Selank’s clinical evidence comes from small Russian studies that focused on anxiety disorders and related symptoms.

A 2008 study included 62 patients with generalized anxiety disorder or neurasthenia. Thirty received Selank, and 32 received medazepam. The authors reported similar changes on standard anxiety scales and additional anti-fatigue effects with Selank.⁴

The study used an active comparator and did not include a placebo group. It was also Russian-language and developer-affiliated.⁴ Those details do not erase the reported result, but they limit how confidently you can apply it to your own care.

A 2014 study compared Selank with phenazepam in 60 patients with anxiety disorders. The authors reported anxiety-related effects and mild nootropic effects with Selank.⁵ The publication did not describe randomization or blinding, which leaves basic questions about allocation and outcome assessment unanswered.

A 2015 study included 40 patients who took Selank with phenazepam and 30 who took phenazepam alone. The combination group reported fewer phenazepam side effects.⁶ This design evaluated Selank as an addition to another drug. It did not establish how Selank performs by itself against placebo.

Taken together, the Selank studies provide a clinical signal worth studying further. They do not establish a reliable treatment effect. If anxiety is your main concern, your physician weighs symptom severity, other medications, sleep, stress, and medical causes. That review decides whether an experimental treatment belongs in the conversation.

Semax’s Stroke and Cognition Evidence

Semax’s clinical record centers on neurological questions, and FDA found that record insufficient for the indications it reviewed.¹

A Russian stroke-rehabilitation study included 110 patients. The Semax groups showed higher plasma brain-derived neurotrophic factor (BDNF) and better recovery on a daily-living scale.¹⁰ The published design was not fully described, which makes the size and reliability of the treatment effect difficult to judge.

FDA also found no human pharmacokinetic data for Semax. Pharmacokinetics describes how a substance is absorbed, distributed, and cleared. Without that information, physicians have less evidence for interpreting exposure and comparing formulations.¹

The FDA briefing identified a possible antithrombotic effect and an abuse-potential signal in mice.¹ Animal signals do not prove the same effect in humans. They identify questions that need better safety data.

The full clinical record, FDA review, and evidence limits are covered in our Semax peptide guide. If cognition or focus is your concern, Semax should not replace an evaluation of sleep, thyroid function, hormone levels, medications, and mental health.

The Direct Human Comparison

Only one human study directly examined both Semax and Selank, and it measured brain connectivity rather than symptom improvement.

The study included 52 healthy participants who received Semax, Selank, or placebo before resting-state brain scans. Both peptides changed connectivity involving the right amygdala, with shared and peptide-specific patterns.¹¹

The imaging changes appeared within minutes. The study did not measure anxiety relief, attention, memory, stroke recovery, or daily function.¹¹ A brain-scan change therefore cannot tell you whether either peptide produced a useful clinical outcome.

A separate laboratory study found that Semax and Selank inhibited enzymes that break down enkephalins in human serum.³ That experiment took place outside the body. It provides a possible mechanism for future research, but it does not establish a treatment benefit.

Both peptides can produce measurable biological effects under study conditions. Only clinical outcome trials can show whether those effects improve your health.

The U.S. Compounding Path

The October 2026 U.S. Department of Health and Human Services (HHS) draft policy treats Semax and Selank differently.

Appendix A lists six peptide bulk drug substances, including Semax. Appendix B identifies Semax free base for intranasal use.⁷ Selank does not appear in Appendix A.

The Semax listing applies only when all policy conditions are met. The substance must match the listed identity and route. Manufacturing and testing records must address identity, purity, potency, contaminants, and the original manufacturer. Reporting, labeling, patient-specific prescription, and other Federal Food, Drug, and Cosmetic Act requirements also apply.⁷

The policy covers single-active-ingredient products. A Semax and Selank combination would fall outside its terms because Selank is absent from Appendix A and the product would contain more than one active ingredient.⁷

HHS describes the document as a draft enforcement-discretion policy. It does not approve Semax, add Semax to the 503A bulks list, or establish that Semax is safe or effective.^7,12 Compounded drugs are not FDA-approved, so FDA does not review their safety, effectiveness, or quality before marketing.^7,12

FDA lists both Semax and Selank acetate among substances withdrawn by their nominators from Category 2.⁸ Semax later received separate treatment in the HHS draft after the Pharmacy Compounding Advisory Committee reviewed it in July 2026.¹³ Selank did not receive the same treatment.

The draft status could change through comments, later policy revisions, or FDA rulemaking. Your physician and compounding pharmacy must work from the current policy rather than treating the October 2026 document as permanent. Our guide to peptide legality and the HHS policy covers the wider federal framework.

Physician-Led Selection

A physician should start with the problem you want to solve, then determine whether a peptide belongs in the plan.

If anxiety is the concern, the assessment starts with the type, duration, and severity of your symptoms. Your physician also reviews sleep, stress, medication use, and medical causes. Selank’s published studies may inform the discussion, but they do not replace treatments with better evidence.

If focus or cognitive performance is the concern, Semax is not a shortcut around finding the cause. Poor sleep, thyroid dysfunction, hormone changes, medication effects, and mental health conditions can produce similar complaints. Your labs and history help separate those possibilities.

Neither peptide is a sound choice for unsupervised use through a research-product seller. The HHS draft applies to specified compounding circumstances and does not cover research-use-only products or online sellers.⁷ If you compete in tested sport, the U.S. Anti-Doping Agency’s warning gives you another reason to discuss any peptide with qualified medical and sport-governance professionals before use.⁹

Better placebo-controlled trials could change the clinical verdict. A final federal policy that adds or removes substances could also change the access verdict. Until then, the most defensible choice comes from matching your symptoms to the available evidence and reviewing the current regulatory status with a physician.

A fixed peptide protocol cannot account for changes in your labs or symptoms. Ongoing care uses repeat testing to adjust the plan as your numbers change.

The Opt Take on Semax and Selank

A physician should first identify what is driving your anxiety or poor focus, then measure the relevant biomarkers and retest them over time.

A peptide comparison is useful only after your physician understands why you are considering one.

At Opt Health, we start with a blood panel of more than 55 biomarkers and a one-on-one physician review. Your physician reads hormone, inflammation, cardiovascular, and other markers against your symptoms, medications, sleep, and goals. The plan is reassessed with new labs and another physician consultation every three to four months.

Every lab we order gets read by a physician before anyone is offered a treatment. Existing conditions and current medications are reviewed at the initial consultation.

That process matters for focus and anxiety because the same symptom can come from different drivers. A normal isolated result does not explain the full pattern. Your physician looks across related markers and adjusts the plan based on what your numbers do over time.

A treatment plan may include prescriptions, peptides, supplements, or a different course entirely. Physician-guided peptide therapy keeps selection, sourcing, monitoring, and adjustment inside one care plan.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.